Phase 1b, open-Label, dose escalation study of quizartinib in combination with induction and consolidation chemotherapy in Japanese patients with newly diagnosed acute myeloid leukemia (AML)

Trial Profile

Phase 1b, open-Label, dose escalation study of quizartinib in combination with induction and consolidation chemotherapy in Japanese patients with newly diagnosed acute myeloid leukemia (AML)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Quizartinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 19 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 13 Jul 2016 Planned number of patients changed from 12 to 18.
    • 13 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top